PE20150228A1 - Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida - Google Patents

Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida

Info

Publication number
PE20150228A1
PE20150228A1 PE2014002405A PE2014002405A PE20150228A1 PE 20150228 A1 PE20150228 A1 PE 20150228A1 PE 2014002405 A PE2014002405 A PE 2014002405A PE 2014002405 A PE2014002405 A PE 2014002405A PE 20150228 A1 PE20150228 A1 PE 20150228A1
Authority
PE
Peru
Prior art keywords
pyridin
propharm
ilmethylamine
phosphoramid
quinazolin
Prior art date
Application number
PE2014002405A
Other languages
English (en)
Spanish (es)
Inventor
Jayakumar S Warrier
Navnath Dnyanoba Yadav
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20150228A1 publication Critical patent/PE20150228A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2014002405A 2012-06-11 2013-06-10 Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida PE20150228A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261657913P 2012-06-11 2012-06-11

Publications (1)

Publication Number Publication Date
PE20150228A1 true PE20150228A1 (es) 2015-02-19

Family

ID=48670111

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002405A PE20150228A1 (es) 2012-06-11 2013-06-10 Profarmacos de acido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida

Country Status (34)

Country Link
US (1) US9238666B2 (enExample)
EP (1) EP2858987B1 (enExample)
JP (1) JP6234450B2 (enExample)
KR (1) KR102092984B1 (enExample)
CN (1) CN104350048B (enExample)
AR (1) AR091402A1 (enExample)
AU (1) AU2013274619B2 (enExample)
BR (1) BR112014030629B1 (enExample)
CA (1) CA2876359C (enExample)
CL (1) CL2014003361A1 (enExample)
CO (1) CO7160032A2 (enExample)
CY (1) CY1120432T1 (enExample)
DK (1) DK2858987T3 (enExample)
EA (1) EA024692B1 (enExample)
ES (1) ES2675314T3 (enExample)
HR (1) HRP20180815T8 (enExample)
HU (1) HUE039210T2 (enExample)
IL (1) IL236074A (enExample)
LT (1) LT2858987T (enExample)
MX (1) MX356699B (enExample)
MY (1) MY169219A (enExample)
NZ (1) NZ703632A (enExample)
PE (1) PE20150228A1 (enExample)
PH (1) PH12014502747B1 (enExample)
PL (1) PL2858987T3 (enExample)
PT (1) PT2858987T (enExample)
RS (1) RS57376B1 (enExample)
SG (1) SG11201408076WA (enExample)
SI (1) SI2858987T1 (enExample)
SM (1) SMT201800369T1 (enExample)
TN (1) TN2014000499A1 (enExample)
TW (1) TWI571470B (enExample)
WO (1) WO2013188254A1 (enExample)
ZA (1) ZA201500161B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9403834B2 (en) * 2013-03-11 2016-08-02 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
CN105008366B (zh) * 2013-03-11 2017-11-14 百时美施贵宝公司 作为钾离子通道抑制剂的吡咯并哒嗪类化合物
KR20180084049A (ko) * 2015-11-19 2018-07-24 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 제약 화합물의 아민 전구약물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
AR049847A1 (es) 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
EP1838690A2 (en) * 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
EP2473487B1 (en) 2009-09-03 2016-10-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP2016516691A (ja) * 2013-03-11 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カリウムイオンチャネル阻害剤としてのイソキノリン
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors

Also Published As

Publication number Publication date
MX356699B (es) 2018-06-11
TW201402592A (zh) 2014-01-16
EP2858987A1 (en) 2015-04-15
PH12014502747A1 (en) 2015-02-02
CN104350048B (zh) 2016-12-07
AR091402A1 (es) 2015-02-04
AU2013274619A1 (en) 2015-01-29
CO7160032A2 (es) 2015-01-15
JP6234450B2 (ja) 2017-11-22
CA2876359A1 (en) 2013-12-19
PH12014502747B1 (en) 2015-02-02
RS57376B1 (sr) 2018-08-31
CN104350048A (zh) 2015-02-11
NZ703632A (en) 2016-01-29
JP2015521598A (ja) 2015-07-30
CY1120432T1 (el) 2019-07-10
BR112014030629A2 (pt) 2017-06-27
WO2013188254A1 (en) 2013-12-19
EA201492256A1 (ru) 2016-05-31
SI2858987T1 (en) 2018-06-29
KR20150023667A (ko) 2015-03-05
PL2858987T3 (pl) 2018-08-31
CL2014003361A1 (es) 2015-05-29
PT2858987T (pt) 2018-07-04
HRP20180815T8 (hr) 2019-02-08
US20150175641A1 (en) 2015-06-25
ZA201500161B (en) 2017-04-26
IL236074A0 (en) 2015-02-01
MY169219A (en) 2019-03-19
SMT201800369T1 (it) 2018-09-13
HRP20180815T1 (hr) 2018-06-29
DK2858987T3 (en) 2018-07-30
HK1203928A1 (en) 2015-11-06
MX2014014525A (es) 2015-02-24
SG11201408076WA (en) 2015-01-29
HUE039210T2 (hu) 2018-12-28
EA024692B1 (ru) 2016-10-31
LT2858987T (lt) 2018-07-10
AU2013274619B2 (en) 2017-09-28
ES2675314T3 (es) 2018-07-10
TWI571470B (zh) 2017-02-21
KR102092984B1 (ko) 2020-03-24
US9238666B2 (en) 2016-01-19
BR112014030629B1 (pt) 2021-12-21
EP2858987B1 (en) 2018-04-25
IL236074A (en) 2016-08-31
CA2876359C (en) 2020-01-21
TN2014000499A1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PE20150974A1 (es) Derivados de piridina
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
UY35381A (es) Pirrolotriazinas como inhibidores del canal del ion potasio
CO6551666A2 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
MX345763B (es) Nuevos macrociclos como inhibidores del factor xia.
PH12017501160A1 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
MX373196B (es) Inhibidores de histona desacetilasa novedosos.
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
CO6561783A2 (es) Inhibidores del virus flaviviridae
MX2016001304A (es) Polimorfo de inhibidores de syk.
CR20120296A (es) Nuevos compuestos de espiropiperidina
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
ES2657549T3 (es) Piridopirazinas sustituidas como nuevos inhibidores de SYK
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
EA201490643A1 (ru) Новые производные бетулиновой кислоты с противовирусной активностью
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
DOP2014000177A (es) Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2
CO7160032A2 (es) Profarmacos de ácido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida
PE20141021A1 (es) DERIVADOS DE TIENO [2,3-d] PIRIMIDINA COMO INHIBIDORES DEL CANAL DE POTASIO

Legal Events

Date Code Title Description
FG Grant, registration